Catalio Capital Management, LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1958125.
- Reported value$532.1m
- Positions39
Holdings: 39 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Avalyn Pharmaceuticals IncAVLN | COM SHS | 05348Y105 | 55.2 | 10.4% | 1,675,830 | New+1,675,830 | |
| Johnson & JohnsonJNJ | COM | 478160104 | 35.3 | 6.6% | 138,946 | New+138,946 | |
| Gilead Sciences IncGILD | COM | 375558103 | 34.0 | 6.4% | 269,309 | Added+105,404 | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 33.9 | 6.4% | 455,041 | Added+23,027 | |
| Syndax Pharmaceuticals IncSNDX | COM | 87164F105 | 26.6 | 5.0% | 1,215,698 | Added+172,028 | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 26.5 | 5.0% | 562,672 | Reduced−475,312 | |
| Bristol-Myers Squibb CoBMY | COM | 110122108 | 23.8 | 4.5% | 412,961 | Reduced−7,766 | |
| Parabilis Medicines IncPBLS | COM | 698955101 | 22.6 | 4.2% | 824,043 | New+824,043 | |
| Natera IncNTRA | COM | 632307104 | 22.3 | 4.2% | 82,181 | Added+11,274 | |
| Incyte CorpINCY | COM | 45337C102 | 21.7 | 4.1% | 191,627 | Added+9,526 | |
| Septerna IncSEPN | COM | 81734D104 | 18.0 | 3.4% | 536,152 | Added+241,792 | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 17.5 | 3.3% | 648,722 | Added+209,681 | |
| Heartflow IncHTFL | COM | 42238D107 | 17.1 | 3.2% | 583,055 | Added+179,467 | |
| Corvus Pharmaceuticals IncCRVS | COM | 221015100 | 16.1 | 3.0% | 1,080,888 | Added+188,955 | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 14.8 | 2.8% | 276,550 | Added+21,171 | |
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 13.1 | 2.5% | 106,799 | New+106,799 | |
| Disc Medicine IncIRON | COM | 254604101 | 11.7 | 2.2% | 159,384 | Added+36,406 | |
| Edwards Lifesciences CorpEW | COM | 28176E108 | 11.3 | 2.1% | 124,778 | Reduced−19,829 | |
| Axsome Therapeutics Inc.AXSM | COM | 05464T104 | 10.6 | 2.0% | 43,182 | New+43,182 | |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 10.6 | 2.0% | 316,252 | Reduced−534,545 | |
| Kailera Therapeutics IncKLRA | COMMON STOCK | 482931102 | 10.3 | 1.9% | 468,750 | New+468,750 | |
| Karyopharm Therapeutics IncKPTI | COM NEW | 48576U205 | 9.2 | 1.7% | 940,855 | Added+43,146 | |
| Odyssey Therapeutics IncODTX | COMMON STOCK | 67613T104 | 8.6 | 1.6% | 457,839 | New+457,839 | |
| Ascendis Pharma A/S | ORD SHS | K08588103 | 8.5 | 1.6% | 31,759 | New+31,759 | |
| Kardigan IncKARD | COM | 485925101 | 7.5 | 1.4% | 312,500 | New+312,500 | |
| Eledon Pharmaceuticals IncELDN | COM | 28617K101 | 6.7 | 1.3% | 1,695,071 | Added+55,255 | |
| 4D Molecular Therapeutics inFDMT | COM | 35104E100 | 6.3 | 1.2% | 471,254 | New+471,254 | |
| Veradermics IncMANE | COMMON STOCK | 922967104 | 5.6 | 1.1% | 45,856 | Reduced−127,726 | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 5.4 | 1.0% | 244,929 | Reduced−38,025 | |
| Fractyl Health Inc | COM | 35168W103 | 4.9 | 0.9% | 6,168,749 | Added+676,883 | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 4.7 | 0.9% | 148,045 | Added+63,693 | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 3.2 | 0.6% | 32,941 | Reduced−527,367 | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 2.4 | 0.5% | 318,407 | New+318,407 | |
| Protara Therapeutics IncTARA | COM STK | 74365U107 | 2.0 | 0.4% | 520,148 | Reduced−59,876 | |
| Hyperfine IncHYPR | COM CL A | 44916K106 | 1.8 | 0.3% | 1,320,041 | Unchanged | |
| Ataibeckley Inc | COM SHS | 04650F101 | 1.0 | 0.2% | 196,858 | Unchanged | |
| Metagenomi Therapeutics IncMGX | COM | 59102M104 | 0.6 | 0.1% | 528,993 | Unchanged | |
| Outset Med IncOM | COM NEW | 690145206 | 0.5 | <0.1% | 118,279 | Unchanged | |
| Faeth Therapeutics IncFTH | COM NEW | 81728A207 | 0.4 | <0.1% | 14,718 | Unchanged |
Sold out: 13 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 0.0 | 0.0% | 0 | Sold out−47,193 | |
| Adaptive Biotechnologies CorADPT | COM | 00650F109 | 0.0 | 0.0% | 0 | Sold out−722,784 | |
| Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 0.0 | 0.0% | 0 | Sold out−129,111 | |
| Boston Scientific CorpBSX | COM | 101137107 | 0.0 | 0.0% | 0 | Sold out−299,318 | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 0.0 | 0.0% | 0 | Sold out−215,501 | |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−426,551 | |
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 0.0 | 0.0% | 0 | Sold out−83,554 | |
| Phathom Pharmaceuticals IncPHAT | COM | 71722W107 | 0.0 | 0.0% | 0 | Sold out−247,767 | |
| Soleno Therapeutics Inc | COM | 834203309 | 0.0 | 0.0% | 0 | Sold out−577,808 | |
| Supernus PharmaceuticalsSUPN | COM | 868459108 | 0.0 | 0.0% | 0 | Sold out−62,019 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−409,031 | |
| Tyra Biosciences IncTYRA | COM | 90240B106 | 0.0 | 0.0% | 0 | Sold out−67,285 | |
| Uniqure NV | SHS | N90064101 | 0.0 | 0.0% | 0 | Sold out−491,116 |
Source: SEC EDGAR, Form 13F-HR, accession 0001958125-26-000005 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.